{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:23:55Z","timestamp":1783470235875,"version":"3.55.0"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T00:00:00Z","timestamp":1733961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Due to its potent antibacterial activity, vancomycin is widely used in the treatment of sepsis. Therapeutic drug monitoring (TDM) can optimize personalized vancomycin dosing regimens, enhancing therapeutic efficacy and minimizing nephrotoxic risk, thereby potentially improving patient outcomes. However, it remains uncertain whether TDM affects the mortality rate among sepsis patients or whether age plays a role in this outcome.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We analyzed data from the Medical Information Mart of Intensive Care\u2013IV database, focusing on sepsis patients who were admitted to the intensive care unit (ICU) and treated with vancomycin. The primary variable of interest was the use of vancomycin TDM during the ICU stay. The primary outcome was 30-day mortality. To control for potential confounding factors and evaluate associations, we used Cox proportional hazards regression and propensity score matching (PSM). Subgroup and sensitivity analyses were performed to assess the robustness of our findings. Furthermore, restricted cubic spline models were utilized to investigate the relationship between age and mortality among different groups of sepsis patients, to identify potential non-linear associations.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 14,053 sepsis patients met the study criteria, of whom 6,826 received at least one TDM during their ICU stay. After PSM, analysis of 4,329 matched pairs revealed a significantly lower 30-day mortality in the TDM group compared with the non-TDM group (23.3% vs.27.7%, <jats:italic>p<\/jats:italic> &amp;lt; 0.001). Multivariable Cox proportional hazards regression showed a significantly reduced 30-day mortality risk in the TDM group [adjusted hazard ratio (HR): 0.66; 95% confidence interval (CI): 0.61\u20130.71; <jats:italic>p<\/jats:italic> &amp;lt; 0.001]. This finding was supported by PSM-adjusted analysis (adjusted HR: 0.71; 95% CI: 0.66\u20130.77; <jats:italic>p<\/jats:italic> &amp;lt; 0.001) and inverse probability of treatment weighting analysis (adjusted HR: 0.72; 95% CI: 0.67\u20130.77; <jats:italic>p<\/jats:italic> &amp;lt; 0.001). Kaplan\u2013Meier survival curves also indicated significantly higher 30-day survival in the TDM group (log-rank test, <jats:italic>p<\/jats:italic> &amp;lt; 0.0001). Subgroup analyses by gender, age, and race yielded consistent results. Patients with higher severity of illness\u2014indicated by sequential organ failure assessment scores \u22656, acute physiology score III \u226540, or requiring renal replacement therapy, vasopressors, or mechanical ventilation\u2014experienced more pronounced mortality improvement from vancomycin TDM compared with those with lower severity scores or not requiring these interventions. The results remained robust after excluding patients with ICU stays &amp;lt;48 h, those with methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic> infections, or when considering only patients with septic shock. In subgroup analyses, patients under 65 years (adjusted HR: 0.50; 95% CI: 0.43\u20130.58) benefited more from vancomycin TDM than those aged 65 years and older (adjusted HR: 0.75; 95% CI: 0.67\u20130.83). Notably, sepsis patients aged 18\u201350 years had the lowest mortality rate among all age groups, at 15.2% both before and after PSM. Furthermore, in this age group, vancomycin TDM was associated with a greater reduction in 30-day mortality risk, with adjusted HRs of 0.32 (95% CI: 0.24\u20130.41) before PSM and 0.30 (95% CI: 0.22\u20130.32) after PSM.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Vancomycin TDM is associated with reduced 30-day mortality in sepsis patients, with the most significant benefit observed in patients aged 18\u201350. This age group exhibited the lowest mortality rates and experienced the greatest reduction in mortality following TDM compared with older patients.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2024.1498337","type":"journal-article","created":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T04:29:30Z","timestamp":1733977770000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Impact of vancomycin therapeutic drug monitoring on mortality in sepsis patients across different age groups: a propensity score-matched retrospective cohort study"],"prefix":"10.3389","volume":"11","author":[{"given":"Huaidong","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruichang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangwu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruolun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qilin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xunlong","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,12,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1097\/CCM.0000000000005886","article-title":"Association between levels of intensive care and in-hospital mortality in patients hospitalized for sepsis stratified by sequential organ failure assessment scores","volume":"51","author":"Ohbe","year":"2023","journal-title":"Crit Care Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study","volume":"395","author":"Rudd","year":"2020","journal-title":"Lancet."},{"key":"B4","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1056\/NEJMp1707170","article-title":"Recognizing sepsis as a global health priority - a WHO resolution","volume":"377","author":"Reinhart","year":"2017","journal-title":"N Engl J Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/s13054-021-03736-w","article-title":"Initial antimicrobial management of sepsis","volume":"25","author":"Niederman","year":"2021","journal-title":"Crit Care."},{"key":"B6","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1086\/491709","article-title":"Vancomycin: a history","volume":"42","author":"Levine","year":"2006","journal-title":"Clin Infect Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis."},{"key":"B8","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med."},{"key":"B9","unstructured":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists214\n            MartinJH\n            NorrisR\n            BarrasM\n            RobertsJ\n            MorrisR\n            DoogueM\n          Clin Biochem Rev.312010"},{"key":"B10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1097\/FTD.0000000000000944","article-title":"Optimal practice for vancomycin therapeutic drug monitoring: position statement from the anti-infectives committee of the international association of therapeutic drug monitoring and clinical toxicology","volume":"44","author":"Reuter","year":"2022","journal-title":"Ther Drug Monit."},{"key":"B11","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.ijantimicag.2018.09.021","article-title":"Plasma and interstitial fluid population pharmacokinetics of vancomycin in critically ill patients with sepsis","volume":"53","author":"Abraham","year":"2019","journal-title":"Int J Antimicrob Agents."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00228-019-02694-1","article-title":"Vancomycin population pharmacokinetics for adult patients with sepsis or septic shock: are current dosing regimens sufficient?","volume":"75","author":"Heffernan","year":"2019","journal-title":"Eur J Clin Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/phar.2367","article-title":"Vancomycin pharmacokinetics in obese patients with sepsis or septic shock","volume":"40","author":"Masich","year":"2020","journal-title":"Pharmacotherapy."},{"key":"B14","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/jpids\/piaa057","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm."},{"key":"B15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jointm.2023.12.007","article-title":"Understanding antimicrobial pharmacokinetics in critically ill patients to optimize antimicrobial therapy: a narrative review","volume":"4","author":"Roger","year":"2024","journal-title":"J Intensive Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1002\/phar.2234","article-title":"Conversion from vancomycin trough concentration-guided dosing to area under the curve-guided dosing using two sample measurements in adults: implementation at an academic medical center","volume":"39","author":"Meng","year":"2019","journal-title":"Pharmacotherapy."},{"key":"B17","doi-asserted-by":"publisher","first-page":"ofae002","DOI":"10.1093\/ofid\/ofae002","article-title":"Model-informed precision dosing improves outcomes in patients receiving vancomycin for gram-positive infections","volume":"11","author":"Hall","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"B18","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1248\/bpb.26.876","article-title":"Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin","volume":"26","author":"Iwamoto","year":"2003","journal-title":"Biol Pharm Bull."},{"key":"B19","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1136\/ejhpharm-2022-003455","article-title":"Clinical benefits of therapeutic drug monitoring of vancomycin therapy in patients with postoperative intracerebral hemorrhage: a retrospective cohort study","volume":"31","author":"Liu","year":"2024","journal-title":"Eur J Hosp Pharm."},{"key":"B20","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1128\/AAC.01179-20","article-title":"Effectiveness of vancomycin dosing guided by therapeutic drug monitoring in adult patients receiving extracorporeal membrane oxygenation","author":"Marella","year":"2020","journal-title":"Antimicrob Agents Chemother."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1016\/j.clinthera.2017.06.008","article-title":"Clinical outcome and antimicrobial therapeutic drug monitoring for the treatment of infections in acute burn patients","volume":"39","author":"Machado","year":"2017","journal-title":"Clin Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e77169","DOI":"10.1371\/journal.pone.0077169","article-title":"Benefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysis","volume":"8","author":"Ye","year":"2013","journal-title":"PLoS ONE."},{"key":"B23","doi-asserted-by":"publisher","first-page":"S363","DOI":"10.1093\/cid\/ciaa1536","article-title":"Evidence-based guideline for therapeutic drug monitoring of vancomycin: 2020 update by the division of therapeutic drug monitoring, Chinese pharmacological society","volume":"71","author":"He","year":"2020","journal-title":"Clin Infect Dis."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1007\/s40265-017-0764-7","article-title":"The whole price of vancomycin: toxicities, troughs, and time","volume":"77","author":"Jeffres","year":"2017","journal-title":"Drugs."},{"key":"B25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/01.CCM.0000194535.82812.BA","article-title":"The effect of age on the development and outcome of adult sepsis","volume":"34","author":"Martin","year":"2006","journal-title":"Crit Care Med."},{"key":"B26","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1007\/s12519-023-00689-8","article-title":"Sepsis heterogeneity","volume":"19","author":"Wang","year":"2023","journal-title":"World J Pediatr."},{"key":"B27","doi-asserted-by":"publisher","first-page":"25","DOI":"10.31083\/j.rcm2504132","article-title":"Sex differences in the epidemiology, risk factors, and prognosis of malignant ventricular arrhythmias in sepsis patients","author":"Li","year":"2024","journal-title":"RCM."},{"key":"B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41597-023-01945-2","article-title":"MIMIC-IV, a freely accessible electronic health record dataset","volume":"10","author":"Johnson","year":"2023","journal-title":"Sci Data."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","article-title":"Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration","volume":"4","author":"Vandenbroucke","year":"2007","journal-title":"PLoS Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ins.2022.01.056","article-title":"Nearest neighbor imputation for categorical data by weighting of attributes","volume":"592","author":"Faisal","year":"2022","journal-title":"Inf Sci."},{"key":"B31","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.jcrc.2009.09.001","article-title":"The effect of comorbidity and age on hospital mortality and length of stay in patients with sepsis","volume":"25","author":"Yang","year":"2010","journal-title":"J Crit Care."},{"key":"B32","doi-asserted-by":"publisher","first-page":"385","DOI":"10.21203\/rs.3.rs-2131537\/v1","article-title":"Association between age and the host response in critically ill patients with sepsis","volume":"26","author":"Michels","year":"2022","journal-title":"Crit Care."},{"key":"B33","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fmed.2017.00020","article-title":"Sepsis and immunosenescence in the elderly patient: a review","volume":"4","author":"Mart\u00edn","year":"2017","journal-title":"Front Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.accpm.2018.10.006","article-title":"Understanding the impact of pathophysiological alterations during critical illness on drug pharmacokinetics","volume":"37","author":"Jamal","year":"2018","journal-title":"Anaesth Crit Care Pain Med."},{"key":"B35","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1186\/s13054-018-2155-1","article-title":"Pharmacokinetics-pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients","volume":"22","author":"Veiga","year":"2018","journal-title":"Crit Care."},{"key":"B36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/antibiotics11091193","article-title":"Tissue penetration of antimicrobials in intensive care unit patients: a systematic review-part II","author":"Viaggi","year":"2022","journal-title":"Antibiotics."},{"key":"B37","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1080\/17425255.2020.1750597","article-title":"Pharmacokinetic and pharmacodynamic considerations in antimicrobial therapy for sepsis","volume":"16","author":"Fujii","year":"2020","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/phar.1638","article-title":"Vancomycin trough concentration as a predictor of clinical outcomes in patients with staphylococcus aureus bacteremia: a meta-analysis of observational studies","volume":"35","author":"Prybylski","year":"2015","journal-title":"Pharmacotherapy."},{"key":"B39","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12879-021-05858-6","article-title":"The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing","volume":"21","author":"Tsutsuura","year":"2021","journal-title":"BMC Infect Dis."},{"key":"B40","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.cmi.2019.10.029","article-title":"Vancomycin area under the curve to minimum inhibitory concentration ratio predicting clinical outcome: a systematic review and meta-analysis with pooled sensitivity and specificity","volume":"26","author":"Dalton","year":"2020","journal-title":"Clin Microbiol Infect."},{"key":"B41","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1093\/cid\/ciz051","article-title":"Vancomycin area under the curve and acute kidney injury: a meta-analysis","volume":"69","author":"Aljefri","year":"2019","journal-title":"Clin Infect Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"106958","DOI":"10.1016\/j.ijantimicag.2023.106958","article-title":"Association between vancomycin therapeutic drug monitoring and clinical outcomes in treating neonatal sepsis","volume":"62","author":"Chung","year":"2023","journal-title":"Int J Antimicrob Agents."},{"key":"B43","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s15010-020-01568-4","article-title":"Association between high vancomycin minimum inhibitory concentration and clinical outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: a meta-analysis","volume":"49","author":"Ishaq","year":"2021","journal-title":"Infection."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1186\/s12879-024-09927-4","article-title":"Effect of low vs. high vancomycin trough level on the clinical outcomes of adult patients with sepsis or gram-positive bacterial infections: a systematic review and meta-analysis","volume":"24","author":"Chander","year":"2024","journal-title":"BMC Infect Dis."},{"key":"B45","doi-asserted-by":"publisher","first-page":"e100","DOI":"10.1097\/CCM.0000000000005228","article-title":"Bayesian models for therapeutic monitoring of vancomycin in the critically ill: what should they predict?","volume":"50","author":"Briassoulis","year":"2022","journal-title":"Crit Care Med."},{"key":"B46","doi-asserted-by":"publisher","first-page":"107005","DOI":"10.1016\/j.ijantimicag.2023.107005","article-title":"Serum concentration of continuously administered vancomycin influences efficacy and safety in critically ill adults: a systematic review","volume":"62","author":"Viertel","year":"2023","journal-title":"Int J Antimicrob Agents."},{"key":"B47","doi-asserted-by":"publisher","first-page":"403","DOI":"10.2147\/IDR.S219989","article-title":"Serum concentration of vancomycin is a diagnostic predictor of nephrotoxic acute kidney injury in septic patients in clinical and surgical wards","volume":"13","author":"Zamoner","year":"2020","journal-title":"Infect Drug Resist"},{"key":"B48","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1186\/s12879-024-09227-x","article-title":"Association between trough serum vancomycin concentration and vancomycin-associated acute kidney injury and 30-day mortality in critically ill elderly adults","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Infect Dis."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1498337\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T04:29:36Z","timestamp":1733977776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2024.1498337\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,12]]},"references-count":48,"alternative-id":["10.3389\/fmed.2024.1498337"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2024.1498337","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,12]]},"article-number":"1498337"}}